This segment focuses on the development, marketing, and commercialization of the NeuroStar Advanced Therapy System, a non-invasive transcranial magnetic stimulation (TMS) device used to treat major depressive disorder (MDD) in adults. Research and development efforts are directed towards improving the efficacy, safety, and patient experience of TMS therapy. This includes optimizing stimulation protocols, developing advanced coil designs, and integrating digital health technologies to personalize treatment. The segment addresses the significant unmet need for effective and well-tolerated treatments for depression, offering an alternative to medication and electroconvulsive therapy (ECT). Neuronetics aims to expand access to NeuroStar TMS therapy through strategic partnerships and collaborations with mental health providers, while also focusing on clinical validation and regulatory compliance to ensure patient safety and treatment outcomes. Future opportunities include exploring new therapeutic applications of TMS for other neurological and psychiatric disorders.